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Tripartitemotif 39 (Trim39) is a RINGdomain-containing E3ubiquitin
ligase able to inhibit the anaphase-promoting complex (APC/C)
directly. Through analysis of Trim39 function in p53-positive and
p53-negative cells, we have found, surprisingly, that p53-positive
cells lacking Trim39 could not traverse the G1/S transition. This
effect did not result from disinhibition of the APC/C. Moreover,
although Trim39 loss inhibited etoposide-induced apoptosis in p53-
negative cells, apoptosis was enhanced by Trim39 knockdown in
p53-positive cells. Furthermore, we show here that the Trim39 can
directly bind and ubiquitylate p53 in vitro and in vivo, leading to p53
degradation. Depletion of Trim39 significantly increased p53 pro-
tein levels and cell growth retardation in multiple cell lines. We
found that the relative importance of Trim39 and the well-charac-
terized p53-directed E3 ligase, murine double minute 2 (MDM2),
varied between cell types. In cells that were relatively insensitive
to the MDM2 inhibitor, nutlin-3a, apoptosis could be markedly en-
hanced by siRNA directed against Trim39. As such, Trim39may serve
as a potential therapeutic target in tumorswithWTp53whenMDM2
inhibition is insufficient to elevate p53 levels and apoptosis.
E3 ubiquitin ligases are essential for cell cycle transitions, con-trolling the abundance of many key cell cycle regulators, such
as cyclin proteins and their inhibitors (1). In addition, E3 ligases,
such as murine double minute 2 (MDM2), a ligase that targets the
p53 tumor suppressor, are known to control the cellular response
to DNA damage, including cell cycle arrest and the induction of
apoptosis (2–4).
Recently, we reported that involvement of the tripartite motif
39 (Trim39) E3 ubiquitin ligase in controlling DNA damage-
induced apoptosis through inhibition of the anaphase promoting
complex (APC/C), a multiprotein ubiquitin ligase that controls
multiple cell cycle regulators, including cyclins, geminin, and
others (5). Surprisingly, analysis of cell cycle progression in cells
lacking Trim39 now suggests that it also might be important for
G1/S progression/initiation of DNA replication in some cell
types but that a target other than the APC/C was likely involved.
The sequence-specific transcription factor p53 controls a host
of genes important for cell death and proliferation (6). The p53
protein is crucial for protecting cells in times of stress through
a combination of cell cycle arrest, apoptosis, cellular senescence,
DNA repair, and autophagy (7, 8). A variety of stressors can engage
the p53 pathway, and p53 mutations, often lying within the p53
DNA-binding domain or within its protein interaction domains, are
present in greater than half of human cancer cases (9, 10).
Given the centrality of p53 in the cellular stress response and
the potential deleterious impact of alterations in p53 levels (e.g.,
cell cycle arrest, cell death) under nonstressed conditions, levels
of cellular p53 are tightly controlled via ubiquitin-mediated pro-
teasomal degradation (11, 12). The most intensively studied p53-
directed E3 ligase is MDM2, proven in many settings to promote
p53 proteasomal degradation (2–4). Indeed, MDM2 inhibitors,
such as nutlin-3a, are potential cancer therapeutics aimed at
increasing p53 abundance to reduce proliferation and enhance
tumor cell death/senescence (13, 14). Despite the importance of
MDM2 in regulating p53 levels, p53 is susceptible to degradation
in MDM2-deficient mice (15), indicating the presence of other
E3 ligases able to target p53. In this regard, several E3 ligases,
including Pirh2, COP1, ARF-BP1, CHIP, CARP1, and CARP2,
can promote p53 ubiquitylation and degradation under specific
circumstances and/or in specific cell types (12).
Here, we report that the Trim39 E3 ubiquitin ligase, previously
identified as a regulator of the APC/C, has a dual role as a direct
E3 ubiquitin ligase for p53. Accordingly, the G1/S arrest observed
following depletion of Trim39 was dependent on p53. The ability
of Trim39 to induce p53 ubiquitylation and degradation did not
depend on the APC/C and was also independent of MDM2. Ac-
cordingly, for several cell lines that were relatively insensitive to
nutlin-3a, depletion of Trim39 increased apoptotic cell death. This
identification of a previously unknown negative regulator of p53
suggests that there are likely to be as yet unexplored strategies for
elevating p53 for therapeutic benefit.
Results
Knockdown of Trim39 Induces G1/S Arrest and Inhibition of Proliferation.
Based on its ability to inhibit the APC/C, we had postulated that
Trim39 protein might be a component of the spindle assembly
checkpoint that prevents APC/C activation when chromosomes are
not properly aligned on the mitotic spindle. To assess this, we
transfected cells with Trim39-directed siRNA able to deplete greater
than 90% of Trim39 from human telomerase reverse transcriptase-
immortalized retinal pigment epithelial cell line (hTERT-RPE)
cells (where we had seen a marked effect on APC/C-mediated pro-
tein degradation), synchronized these cells using a double thymidine
block, released them into nocodazole to disrupt the spindle, and
monitored them by time-lapse microscopy or analyzed their DNA
content by flow cytometry (Fig. S1 A and B). We were surprised to
find that the great majority of cells lacking Trim39 (93%) never
entered mitosis (Fig. S1 A and B). These data suggested that there
might be another critical role for Trim39 in promoting cell cycle
progression. Indeed, proliferation of the RPE cells was markedly
dampened by loss of Trim39, as shown by both cell growth curves
and colony-forming assays (Fig. 1 A and B). Moreover, EdU (5-
ethynyl-2′-deoxyuridine) incorporation was significantly decreased
after knockdown of Trim39 (1.3% vs. 25.9% in control; P < 0.05),
demonstrating that the lack of Trim39 prevented DNA replica-
tion (Fig. 1C and Fig. S1C). Together, these data suggested that
Trim39 has a role in the G1/S transition (under normal, nonstressed
conditions), in addition to its role in controlling apoptosis in response
to DNA damage. Indeed, cell death did not contribute to failure of
Trim39-deficient cells to proliferate, because depletion of Trim39
had little effect on basal rates of cell death in hTERT-RPE cells as
determined by annexin V/propidium iodide (PI) staining (Fig. S1D).
G1 Arrest Induced by Depletion of Trim39 Is Dependent on p53. The
APC/C inhibitor Emi1 enables DNA synthesis by allowing ac-
cumulation of APC/C substrates, such as cyclin A, and other
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factors required for the G1/S transition (16–19). Thus, it
remained possible that Trim39 also controlled G1/S through its
ability to modulate the APC/C. The hTERT-RPE cells were
serum-starved to arrest at G0/G1 phase and then released into
serum-containing medium. As shown in Fig. 2A, the levels of the
APC/C substrates geminin and cyclin A rapidly increased in a
time-dependent manner in control cells, whereas these increases
were not observed in cells treated with Trim39 siRNA. A similar
decrease in cyclin A and geminin accumulation could be seen on
loss of Emi1 (Fig. 2B). However, additional analysis revealed a
fundamental difference between loss of Emi1 and Trim39; pro-
teasome inhibition by MG132 was able to restore cyclin A and
geminin levels following knockdown of Emi1, whereas proteasome
inhibition had a minimal effect on the levels of these proteins
following Trim39 knockdown (Fig. 2B). These data suggested that
the effect of Trim39 on cyclin A and geminin expression was
unlikely to be a result of Trim39-mediated APC/C inhibition.
To address these issues further, we performed a quantitative
real-time PCR assay on control cells or cells treated with Trim39
siRNA. As shown in Fig. 2C, there was a significant decrease in
the levels of cyclin A, geminin, and Emi1 mRNAs in the absence
of Trim39. However, we observed a marked increase in the ex-
pression of mRNAs encoding p21 (but not p27 and p16), MDM2,
and Bax after Trim39 depletion. These genes are well-known
targets of the tumor suppressor p53, raising the possibility that
p53 was involved in some way in the G1/S transition defect ob-
served in cells lacking Trim39. Therefore, we examined the effects
of codepletion of p53 and Trim39. Although the protein levels of
p53 and p21 were increased coordinately with decreased cyclin A
and geminin proteins after depletion of Trim39, control levels of
these proteins were restored after codepletion of Trim39 and p53
(Fig. 2D). These data strongly suggested that the G1/S arrest
resulting from Trim39 depletion in RPE cells was exerted through
p53. Indeed, knockdown of p53 largely (albeit not completely)
restored EdU incorporation and DNA replication following
knockdown of Trim39 (Fig. 2E and Fig. S2 A–C). Extending these
results to other cell types, and consistent with this idea, we found
that depletion of Trim39 decreased EdU incorporation in cells
with WT p53 (A549, U-87 MG, 22Rv1, MCF7, HepG2, and
HCT116 P53+/+) but had either a minor or no effect on EdU
incorporation in p53 mutant or null cells (H1299, T98G, PC3, and
HCT116 P53−/−) (Fig. 2F). Collectively, these data suggest that
Trim39 depletion can induce accumulation of p53 and its target,
p21, resulting in a failure to traverse the G1/S transition.
Trim39 Interacts with p53 and Regulates Its Stability. Given the
effects of Trim39 on p53 levels, we tested whether Trim39 and
p53 could interact. As shown in Fig. 3A, Trim39 and p53 proteins
were both predominantly nuclear and the nuclear fraction of p53
was dramatically increased in abundance following Trim39 de-
pletion (Fig. 3A; also shown in micrographs in Fig. S2D). In
addition, we were able to coimmunoprecipitate p53 and Trim39
with antisera directed against either protein (Fig. 3 B–D and Fig.
S3 A and B). Moreover, we were able to demonstrate a direct
interaction between recombinant Trim39 and p53 proteins in
vitro (Fig. S3 C and D).
Because Trim39 depletion increased p53 protein levels and we
had previously characterized Trim39 as a RING E3 ligase, we
monitored the effect of Trim39 on p53 protein stability and
found, after depletion of Trim39, that the half-life of p53 was
significantly increased (Fig. 4A and Fig. S4 A and B). Impor-
tantly, although protein levels of p21 were also dramatically in-
creased after depletion of Trim39, the half-life of p21 was not
changed, indicating that Trim39 does not regulate protein levels
of p21 directly (Fig. 4A and Fig. S4 A and B). Rather, it is likely
that changes in p21 levels reflect changes in its transcriptional
activator, p53. Trim39 overexpression decreased levels of p53;
this decrease was dependent on Trim39 E3 ligase activity, be-
cause overexpression of ligase-deficient RING domain mutants
could not promote p53 degradation, despite their ability to bind
p53 (Figs. 3D and 4B). The proteasome inhibitor MG132 allowed
preservation of p53 protein in the face of WT Trim39 overex-
pression, consistent with a role for Trim39 in p53 degradation
(Fig. S5A). In addition, the half-life of exogenously expressed p53
was significantly decreased on coexpression of WT Trim39 and
was actually increased with coexpression of the ligase-deficient
RING domain mutant, likely acting in a dominant-negative fash-
ion to impede endogenous Trim 39 (Fig. S4C).
Furthermore, ectopic expression of WT Trim39, but not the
RING mutant protein, increased p53 ubiquitylation, consistent
with the possibility that Trim39 acts as a p53-directed E3 ubiq-
uitin ligase (Fig. S5B). In support of this idea, Trim39 was able to
ubiquitylate p53 directly in vitro (Fig. 4C and Fig. S5C). Given
that we had previously reported that Trim39 could regulate APC/C
Fig. 1. Trim39 depletion induces cell
growth retardation. (A) hTERT-RPE cells
were transfected with control or Trim39
siRNA, and 1 × 105 cells were seeded in
six-well plates 2 d after siRNA trans-
fection. Cells were counted each day for
4 d. Luc, luciferase (B) Colony assay. Two
days after siRNA transfection, 500 cells
were seeded in 60-mm dishes and cul-
tured for 12 d, and the number of col-
onies was counted. *P < 0.05 vs. control.
(C) hTERT-RPE cells were transfected
with control or Trim39 siRNA, and DNA
replication was monitored by EdU in-
corporation. *P < 0.05 vs. control.
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activity, we speculated that there might be an unknown con-
nection between the APC/C and p53 stability. However, depletion
of CDH1, the activator of APC/C in interphase, or APC11, a core
subunit of the APC/C, had no effect on the ability of Trim39 loss
to elevate p53 levels (Fig. S6 A and B), strongly suggesting that
Trim39 did not affect p53 levels by modulating the APC/C.
Trim39 Can Synergize with MDM2 to Affect Cell Growth and Apoptosis.
There are a number of E3 ubiquitin ligases that have been
reported to act on p53, most prominently MDM2 (2–4). We
wished to determine whether the regulation of p53 stability by
Trim39 was dependent on MDM2; thus, we transfected H1299
cells lacking p53 with control or MDM2 siRNA and examined
the effects of Trim39 on the stability of cotransfected p53. As
shown in Fig. 5A, Trim39 expression was able to induce p53
degradation even in the absence of MDM2. We also did not
observe any direct effects of Trim 39 on MDM2 (or vice versa).
Although Trim 39 knockdown was able to elevate MDM2 levels
Fig. 2. Cell growth inhibition induced by Trim39 depletion is p53-dependent. (A) hTERT-RPE cells were arrested at G1 phase by serum starvation, and cells
were harvested at different time points after adding back media with 10% FBS. The protein levels were detected by Western blotting with the indicated
antibodies. Luc, luciferase. (B) Cells were transfected with control, Trim39, or Emi1 siRNA; 48 h later, cells were treated with MG132 for a further 8 h. Western
blotting was carried out to detect the protein level with the indicated antibodies. (C) Real-time PCR was carried out to detect the gene expression in control or
Trim39 knockdown cells. *P < 0.01 vs. control. (D) Control-shRNA or p53-shRNA cells were transfected with control or Trim39 siRNA, and the protein levels
were detected by Western blotting with the indicated antibodies. (E) Control-shRNA (c-shRNA) or p53-shRNA cells were transfected with control or Trim39
siRNA, and cell proliferation was measured by EdU incorporation. *P < 0.05 vs. control. (F) Panel of cell lines with different p53 background was transfected
with control or Trim39 siRNA, and cell proliferation was detected by EdU incorporation. *P < 0.05 vs. control.
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(Fig. S7A), this was an indirect effect resulting from stabili-
zation of p53 (and thus enhanced MDM2 transcription) be-
cause knockdown of Trim 39 in H1299 cells lacking p53 had
no effect on MDM2 levels (Fig. S7B). Moreover, it appears that
Trim39 and MDM2 bind to different domains of p53, because
p53 mutants (e.g., L14Q/F19S, L22Q/W23S) that were unable
to bind MDM2 bound as well to Trim39 as the WT p53 (20)
(Fig. S8A).
To assess the relative contributions of Trim39 and MDM2 in
controlling cell cycle progression across a range of p53 WT cell
types, we knocked down Trim39, MDM2, or both and measured
EdU incorporation as well as protein levels of p53 and p21. As
shown in Fig. 5B and Fig. S7A, MDM2 and Trim39 knockdown
had a variable impact on cell cycle progression in a variety of
different cell types, with both ligases contributing to the overall p53
and p21 levels as well as possessing the ability to undergo DNA
replication. That said, in cells in which another p53-directed nega-
tive regulator (e.g., murine double minute 4 (MDMX) in JEG-3
cells) is known to play a dominant role, knockdown of neither
Trim39 nor MDM2 (or both) had a significant impact on EdU
incorporation (Fig. S8B).
MDM2 has been considered a promising target for cancer
chemotherapy in that elevating levels of p53 in p53-positive
tumors has the potential to induce cell cycle arrest and/or apo-
ptosis. A number of MDM2 inhibitors have been developed, the
most well known of which is nutlin-3a, a compound that inter-
feres with the binding of p53 to MDM2 (13, 14). In contrast, we
found that nutlin-3a was unable to disrupt the interaction of
Trim39 with p53 (Fig. S8C, compare lanes 2 and 5). Given the
variable relative importance of MDM2 in different cell types,
these data suggest that nutlin-3a might have only partial effects in
cells expressing both MDM2 and Trim39. Therefore, the utility of
nutlin-3a as a therapeutic agent is likely to be restricted by the
population of E3 ligases other than MDM2 (in this case, Trim39)
that contribute to p53 stability in a given cell type, particularly
if those ligases, like Trim39, are refractory to inhibition by nutlin-
3a. Given this, we hypothesized that coinhibition of Trim39
would increase the efficacy of nutlin-3a in killing p53-positive
cells. Consistent with this idea, knockdown of Trim39 enhanced
cell killing by nutlin-3a in p53 WT cells expressing both ligases,
even in cells that were relatively refractory to nutlin-3a, such as
MCF-7 breast cancer cells and A549 lung cancer cells (Fig. 5 C
and D). Importantly, nutlin-3a, either alone or in combination
with Trim39 knockdown, did not kill cancer cells in the absence
of p53 (Fig. 5D; H1299, p53 null cancer cell).
We and others have reported that Trim39 helps to induce
apoptosis following DNA damage, due to its ability to elevate
levels of the Bax activator modulator of apoptosis 1 (MOAP-1;
by means of MOAP-1 degradation by the APC/C). However,
based on the data shown here, it seems that Trim39 can also be
considered antiapoptotic, because its loss can promote stabiliza-
tion of p53 and cell death. To evaluate this issue further, we
knocked down Trim39 in a p53 WT cell (A549) or a p53 null cell
(H1299) and treated with etoposide. As shown in Fig. S8D,
knockdown of Trim39 in the presence of functional p53 enhanced
Fig. 3. Trim39 localizes to the nucleus and interacts with p53. (A) hTERT-RPE
cells were transfected with control or Trim39 siRNA, and cytoplasmic (Cyto)
and nuclear extracts (Nuclei) were fractionated and analyzed by Western
blotting with the indicated antibodies. The asterisk indicates nonspecific
signal. (B and C) hTERT-RPE cells were cross-linked with DSP (Dithiobis[suc-
cinimidyl propionate]), and immunoprecipitation was carried out to detect
the interaction between Trim39 and p53. The asterisk indicates nonspecific
signal. (D) 293T cells were transfected with HA-p53, Trim39 WT, C44A, or
C52A, respectively, as indicated. HA-p53 was immunoprecipitated with anti-
HA antibody, and Western blotting was carried out to detect the interaction
between Trim39 and HA-p53. The asterisk indicates nonspecific signal. c,
control; CE, cell extract; IP, immunoprecipitation; WCL, whole cell lysate.
Fig. 4. Trim39 negatively regulates p53 levels. (A) hTERT-RPE
cells were transfected with control or Trim39 siRNA, and cells
were treated with cycloheximide for the time courses indicated.
The protein levels of p53 and p21 were detected by Western
blotting, quantified using Odyssey software, and plotted
against time to determine protein half-lives. Luc, luciferase.
(B) H1299 cells were transfected with 0.2 μg of HA-p53, 0.1 μg
of pEGFP-C1, and different amounts of Trim39 WT or RING
mutant-encoding plasmids as indicated. Cells were harvested
48 h after transfection, and protein levels were detected by
Western blotting with the indicated antibodies. (C) In vitro
ubiquitylation of p53 by Trim39. 293T cells were transfected
with HA-p53, and HA-p53 was immunoprecipitated and mixed
with myelin basic protein (MBP)-Trim39 and E1/E2/ubiquitin as
indicated for 1 h at 30 °C. Reactions were stopped by adding
sample buffer, and Western blotting was carried out to detect
the ubiquitylation of p53.
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etoposide-induced cell death. In contrast, depletion of Trim39 in
cells lacking p53 dampened etoposide-induced apoptosis, which is
likely due, at least in part, to the effects of Trim39 on the APC/C
and its substrate, MOAP-1, as discussed further below.
Discussion
p53 is a central regulator of cell death, proliferation, and senes-
cence and enables the cell to withstand a wide variety of stressors
(1, 11, 21). For this reason, p53 mutation or deficiency contributes
to a significant fraction of human tumors. Although p53 functions
are required in the face of cellular stress or damage, normal
proliferation of the unperturbed cell requires that intracellular
levels of p53 be restrained. Accordingly, a complex network of
posttranslational modifications (e.g., acetylation, methylation,
phosphorylation) fine-tunes p53’s half-life, rendering it more or
less susceptible to the action of E3 ubiquitin ligases (10, 11).
Although the E3 ubiquitin ligase MDM2 is thought to be the
primary determinant of p53 ubiquitylation and stability in a variety
of cell types, it is clearly not the only relevant p53-directed ligase
(15, 22). Aside from the observation that p53 can be degraded in
MDM2-deficient mice, mutation of the known MDM2-targeted
lysines on p53 does not prevent p53 ubiquitylation and degradation
in cells (22). Moreover, several other E3 ligases, including another
Trim family member, Trim24, are capable of promoting p53 deg-
radation (23). An additional level of complexity stems from the
ability of several of the p53-directed ligases to control each other’s
stability, potentially through direct interaction (24).
In this study, we identified Trim39 as a unique E3 ligase directly
regulating p53 stability and compared the differential effects of
Trim39 and MDM2 knockdown on cell proliferation, p53 stabil-
ity, and p21 induction in multiple cell lines. Interestingly, we
found that the effect of these ligases varied in different cell types.
For example, it seems that Trim39 contributes more signifi-
cantly than MDM2 to cell growth and p53 stability in hTERT-
RPE cells. This may be of potential significance for diseases
of the retina, for example, macular degeneration, where p53
is important for controlling cell death in response to oxidative
stress (25).
For tumors with WT p53, numerous pharmacological ap-
proaches have been taken to upregulate or stabilize p53 protein
(26, 27). Small molecules, such as nutlin-3a and MI-219, are able
to disrupt MDM2–p53 interactions, thereby preventing MDM2-
mediated p53 ubiquitylation (13, 14, 27). Although this approach
to induce p53-mediated cell cycle arrest/apoptosis has been suc-
cessful in many cancer cell lines and xenograft models (and is
under investigation for treating human cancers), significant ex-
pression of other E3 ligases, such as Trim39, would be expected
to diminish the effects of nutlin-3a and similar molecules, unless
the interaction of p53 with these other ligases was also disrupted.
For example, nutlin-3a is already known to be ineffective in cells
that express high levels of MDMX, another known p53-directed
ligase (28–30). Given this, effective elevation of p53 in tumors
may well require a mixture of E3 ligase inhibitors tailored to the
population of p53-directed ligases present in an individual tumor.
Indeed, unique inhibitors that target both MDM2 and MDMX
can impede growth and induce apoptosis in cells with high levels
of both MDM2 and MDMX (26, 31, 32).
In this study, we found that combining nutlin-3a with knock-
down of Trim39 was effective in triggering apoptosis in cells that
were otherwise insensitive to nutlin-3a (e.g., MCF7, A549).
However, this combination was not effective in JEG-3 cells,
Fig. 5. Regulation of p53 stability by Trim39 is independent of MDM2. (A) H1299 cells were transfected with control or MDM2 siRNA first, and cells were then
transfected with HA-p53, Trim39 WT or RING mutants, and pEGFP-C1 as indicated 8 h after siRNA transfection. Cells were harvested 48 h later, and protein
levels were detected by Western blotting with the indicated antibodies. Luc, luciferase; EV, empty vector. (B) hTERT-RPE, MCF7, A549, 22Rv1, or HepG2 cells
were transfected with control, Trim39, or MDM2 siRNA as indicated. Forty-eight hours later, cell proliferation was monitored by EdU incorporation. *P < 0.05
vs. control. (C) MCF7 cells were transfected with control, Trim39, or p53 siRNA as indicated; 48 h later, cells were treated with nutlin-3a for a further 48 h. Cells
were harvested and stained with annexin V and PI, and apoptosis was detected by flow cytometry. *P < 0.05 vs. control. (D) A549 or H1299 cells were
transfected with control or Trim39 siRNA, and 48 h later, cells were treated with nutlin-3a for a further 48 h. Apoptosis (as indicated by the presence of a sub-
G1 population) was detected by flow cytometry. *P < 0.05 vs. control.
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consistent with previous reports documenting high levels of
MDMX expression in these cells.
Many of the E3 ligases that target p53 are also transcriptional
targets of p53 (12). Thus, although E3 ligase inhibition may el-
evate p53, p53, in turn, can promote transcriptional up-regula-
tion of the ligases, potentially overcoming the effect of the
inhibitors. Trim39 does not appear to be regulated by p53, be-
cause depletion of MDM2 significantly increases the levels of
p53 without affecting the levels of Trim39. This might make
Trim39 a promising therapeutic target, but we would note that
depletion of Trim39 significantly increases protein levels of both
p53 and MDM2; induced MDM2 inhibition might therefore
counter the effects of Trim39 inhibition. These observations
again support the notion of an inhibitor mixture as perhaps the
most effective approach to elevating p53 levels.
The identification of Trim39 as a p53-directed ligase raises the
question of how this activity may be related to its previously
described role as an APC/C inhibitor. It does not appear that the
effects of Trim39 on p53 are exerted through the APC/C, nor do
effects on the APC/C require p53 (because Trim39 can inhibit
the APC/C in p53-null cells). Although Trim39 E3 ligase activity
is required to inhibit the APC/C and Trim39 can inhibit the
purified APC/C in vitro, the direct target of Trim39 in the APC/C
has not yet been identified. It is possible that identification of
determinants of p53 recognition/binding by Trim39 may shed
light on the direct interactors of Trim39 within the APC/C. DNA
damage-induced activation of Trim 39 appears to have different
consequences depending on the p53 status of the cell. In the
absence of p53, the Trim 39-mediated inhibition of the APC/C
results in stabilization of MOAP-1, promoting Bax activation and
apoptosis. Additionally, although the ability of Trim39 to inhibit
the APC/C seems to be activated by DNA damage, Trim39
knockdown can affect p53 levels even in the unperturbed cell
cycle. Taken together, these data place Trim39 as a regulator of
several key processes in the proliferative cycle. Additional
experiments will determine whether these functions are entirely
independent and whether they can be manipulated to thera-
peutic advantage in the setting of cancer, eye disease, or other
pathologies involving misregulation of p53.
Materials and Methods
Flow Cytometry Analysis. For the proliferation assay, the Click-iT EdU Alexa
Fluor 488 Flow Cytometry Assay Kit (Invitrogen) was used to measure cell
proliferation following the manufacturer’s instructions. For cell cycle analysis,
cells were fixed in 70% ethanol (vol/vol) (prechilled at −20 °C) for at least 30
min and incubated in 15 μg/mL RNase A (Roche) for 15 min, followed by in-
cubation in 50 μg/mL PI (Sigma) for 30 min. For the annexin V/PI apoptosis
assay, cells (∼1 × 105) were collected and washed once with PBS, followed by
incubation in annexinV (A13201; Invitrogen) solution [2.5 μL of annexinV in 50
μL of annexin V binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2)]
for 15 min and 300 μL of 2 μg/mL PI in annexin V binding buffer. Flow
cytometry analysis was carriedoutwith the useof a Becton–Dickinson FACScan
apparatus and CellQuest software.
Quantitative Real-Time PCR Analysis. Quantitative real-time PCR analysis was
carried out as described (33). All samples were amplified in triplicate, and
every experiment was repeated at least two times. Relative gene expression
was converted using the 2−ΔΔCt method against the internal control GAPDH
housekeeping gene. The primers are listed in SI Materials and Methods.
Measurement of p53 and p21 Half-Life. For protein half-life assays, 100 μg/mL
cycloheximide was added to cell cultures to block protein synthesis. Cells
were collected at the indicated time points, and protein levels were mea-
sured and quantified by Western blotting using LI-COR Biosciences Odyssey
software. The half-lives of proteins were calculated from three independent
experiments. Also shown are immunoblots developed using chemilumines-
cent reagents, but these were not used for quantitation.
In Vitro Ubiquitylation. In vitro ubiquitylation was performed as described
(34). More information is provided in SI Materials and Methods. Additional
information on materials and methods can also be found in SI Materials
and Methods.
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